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Abstract 
Aims  To assess satisfaction with treatment and psychological well-being associated 
with insulin glargine and NPH. Insulin glargine, a new long-acting insulin analogue, 
provides constant, peakless insulin release following once-daily administration and is 
associated with fewer hypoglycaemic episodes, despite metabolic control equivalent 
to that achieved with NPH human basal insulin.  Methods  The Diabetes Treatment 
Satisfaction Questionnaire (DTSQ) and Well-being Questionnaire (W-BQ) were 
completed at baseline and at weeks 8, 20 or 28 by 517 patients with Type 1 diabetes 
participating in a randomized, controlled European trial comparing insulin glargine 
and NPH.  Analysis of covariance was performed on change from baseline scores 
(main effects: treatment and pooled site; covariate: baseline scores).  Results  
Treatment Satisfaction improved with insulin glargine at all time points, including 
endpoint, but deteriorated slightly with NPH.  These differences were significant 
throughout the study (change from baseline to endpoint: +1.27 vs. –0.56; p = 0.0001).  
Outcomes were better with insulin glargine for the DTSQ items, Perceived Frequency 
of Hyperglycaemia and Hypoglycaemia, with statistically significant differences at 
week 28 and endpoint for hyperglycaemia (p = 0.0373 and 0.0379) and at week 20 for 
hypoglycaemia (p = 0.0024).  There was no difference in psychological well-being 
between the treatment groups, with mean scores increasing in both.  Conclusions  
Study participants had treatment-independent improvements in General Well-being.  
Advantages for insulin glargine were seen in significantly improved Treatment 
Satisfaction throughout the study, together with lower Perceived Frequency of 
Hyperglycaemia than for patients on NPH, without a significant increase in Perceived 
Frequency of Hypoglycaemia. 
Witthaus E, Bradley C, Stewart J. HOE 901 (Insulin Glargine) improves satisfaction with intensified 
insulin treatment for type 1 diabetes. Diabetologia, 1999; 42, Suppl. 1, A235 
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Introduction 
New treatments for chronic diseases, including diabetes, are increasingly being 
evaluated for their impact on patient-oriented outcomes, such as treatment satisfaction 
or quality of life.  The attainment and improvement of psychological outcomes is a 
separate but related goal of diabetes care with similar importance to clinical measures 
of control.  Improved metabolic control may contribute to improved psychological 
well-being and vice versa, but a positive correlation cannot be assumed (1-3). 
Therefore, psychological outcomes need to be monitored in conjunction with efforts 
to improve diabetes control to ensure that improved metabolic control is not achieved 
at the expense of psychological outcomes.  
Insulin glargine is a modified human insulin molecule developed to meet the need for 
a basal insulin with a peakless time-action profile over 24 h (4).  Compared with NPH 
once or twice daily, insulin glargine once daily has been shown to yield at least 
similar glycaemic control with fewer hypoglycaemic episodes (5-8).  Our study aimed 
to evaluate the impact of using insulin glargine on satisfaction with treatment and 
psychological well-being. Satisfaction with treatment was expected to be the outcome 
most likely to be improved with insulin glargine because it involves only one 
injection daily and is expected to improve glycaemic control. The well-being measure 
was included with a more exploratory purpose. 
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Patients and methods 
Psychological outcomes were assessed during a randomized, controlled, open-label 
study of the efficacy and safety of insulin glargine versus NPH human insulin.  The 
study population consisted of people with Type 1 diabetes with a minimum 
experience of one year of previous insulin use and was recruited from 10 European 
countries.  The study was approved by the appropriate ethics committees, and signed 
patient consent was obtained prior to the conduct of any study-related procedures. 
At the end of a 4-week screening phase, patients were allocated to insulin glargine or 
NPH by central randomization carried out by an independent agency.  During the 
screening phase, patients were familiarized with the use of the OptiPen® and the 
blood glucose meter (One Touch II®/Lifescan) provided for the determination of 
blood glucose at home.  During the 28-week treatment phase, insulin glargine was 
administered by subcutaneous injection once daily at bedtime while NPH human 
insulin was administered by subcutaneous injection either once or more than once 
daily, depending on the regimen followed prior to the study.  Dose adjustments for 
both insulins were targeted at a self-monitored pre-meal blood glucose concentration 
of 4.4 - 6.7 mmol/l (80 – 120 mg/dl).  In addition to insulin glargine and NPH, regular 
human insulin was administered before each meal.  With the intention of  
standardising other aspects of treatment patients previously using insulin lispro were 
switched to regular human insulin.  Study participants not already using the OptiPen® 
changed over to this injection device for the administration of insulin glargine or 
NPH.  These requirements were driven by the clinical study protocol with the 
intention of standardizing treatment circumstances as far as possible. 
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Questionnaires 
The Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) measures 
satisfaction with treatment regimen (hereafter referred to as Treatment Satisfaction)  
(6 items), Perceived Frequency of Hyperglycaemia (1 item) and Perceived Frequency 
of Hypoglycaemia (1 item) over the past few weeks (3).  The Well-being 
Questionnaire (W-BQ) provides an overall measure of General Well-being (22 items), 
incorporating 4 subscales to measure Depression, Anxiety, Energy and Positive Well-
being (9). The reliability and factor structure of the eight language versions used in 
this study are reported elsewhere (10, 11). To ensure a high response rate, patients 
were asked to complete the questionnaires during the clinic visit and to return them in 
a sealed envelope to study site personnel.  
Statistical analysis 
The primary outcome variables were the changes from baseline to final assessment in 
the DTSQ and W-BQ scores.  Only these two variables were subject to hypothesis 
testing; probability statements for other variables are included for descriptive 
purposes only.  An intention-to-treat (ITT) analysis was performed, including all 
patients who were randomized and treated and who had completed both a pre-
treatment and at least one on-treatment questionnaire.  
The sample size calculation was based on the primary clinical variable, 
glycohaemoglobin.  Nevertheless, prior studies (3, 12, 13) suggested that the sample 
size was more than sufficient to detect meaningful differences in change between 
insulin glargine and NPH in psychological outcomes.  It was estimated that the 
available sample size had at least 80% power to detect an effect size of 0.20.  Effect 
size was defined as the difference between the mean changes from baseline for the 
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two treatment groups divided by the baseline standard deviation.  As for health status 
and other outcomes, an effect size of 0.20 or more is considered clinically meaningful 
for psychological outcomes (14).  
An analysis of covariance (ANCOVA) was performed with treatment and pooled site 
as main effects and baseline score as the covariate.  The difference in mean change 
from baseline was estimated using the adjusted mean together with the associated 
standard error and a 95% confidence interval from the ANCOVA model.  All 
statistical tests were two-sided and performed at a significance level of α = 5%.  Since 
the assumptions of normality of the residuals and equal variances were not met, the 
probability statements were based on the ANCOVA with ranked observations.  In 
order to assess the robustness of the primary model, an expanded model including the 
treatment-by-pooled site and treatment-by-baseline score interactions was examined 
to check whether the interactions were more than just numeric variation.  No 
statistically significant interactions were found. The same ANCOVA was performed 
on the W-BQ12 total scale and subscale scores with an intention to explore the 
responsiveness of this abbreviated version. 
Subgroup analyses were performed to assess the effect of: the number of basal insulin 
injections prior to the study; previous insulin lispro use; and compulsory OptiPen® 
use.  The consistency of treatment effects across countries was also examined. 
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Results 
The psychological ITT population comprised 517 patients, representing 94% of the 
clinical study population.  Patients not included in the analysis provided only baseline 
or on-treatment data.  At baseline there were no significant differences between the 
two treatment groups in terms of demographic, clinical and psychological variables, 
apart from the Energy subscale score of the W-BQ (p = 0.006) (Table 1).  Patients 
allocated to insulin glargine reported more energy at baseline. Treatment Satisfaction 
and General Well-being scores at baseline were high in this population.  Thirty-one 
patients (6%) had a maximum baseline score of 36 for Treatment Satisfaction on the 
DTSQ, and 189 patients (36.6%) scored between 31 and 36.  Five patients (1%) had a 
maximum baseline score of 66 for General Well-being on the W-BQ, and 85 patients 
(16.4%) scored between 58 and 66. 
Table 1.  
DTSQ 
There was a statistically significant mean increase of 1.27 points in the Treatment 
Satisfaction score in the insulin glargine group between study entry and last 
assessment (p = 0.001).  Treatment Satisfaction decreased by 0.56 points in the NPH 
group (p = 0.1499).  The difference between treatments was 1.83 points (p < 0.001, 
Table 2) and represents an effect size of 0.34.  This result remains statistically 
significant even after applying a Bonferroni correction for the large number of 
statistical tests (i.e., 10) reported in this article.  All but one of the six satisfaction 
items contributed to the differences between treatments, with the largest differences 
coming from Item 8 (wish to continue) and Item 4 (convenience).  In contrast, NPH 
produced very little change on most of the items and a decrease on some (Table 3).  
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The changes in Treatment Satisfaction score from baseline to weeks 8, 20 and 28 
revealed a pattern of steady increase over time with insulin glargine; in contrast, there 
was a small but consistent decrease in the NPH group.  The difference between 
treatments was statistically significant at each assessment point (Fig. 1). 
Table 2.  
Table 3.  
Fig. 1.  
Perceptions of blood glucose control 
Both groups of patients reported a consistent mean decrease in Perceived Frequency 
of Hyperglycaemia, both at endpoint and at all interim time points.  This decrease was 
more pronounced with insulin glargine than with NPH and the difference was 
statistically significant at week 28 (p = 0.037) and at endpoint (p = 0.038).  The 
results for Perceived Frequency of Hypoglycaemia revealed a small increase in mean 
change from baseline for both treatment groups at most time points except for week 
20 when there was a significant difference in favour of insulin glargine (p = 0.0024). 
W-BQ 
The mean score for General Well-being showed an increase (i.e., a greater sense of 
well-being) at endpoint of 1.22 points (-0.12; 0.94; 1.44 at weeks 8, 20 and 28, 
respectively) in the insulin glargine group and of 1.57 points (0.31; 0.98; 1.79 at 
weeks 8, 20 and 28, respectively) in the NPH group, with all four subscales 
contributing to these small improvements (Table 2).  While both these within-group 
increases from baseline were statistically significant, there was no difference between 
treatments, either at endpoint or at any interim time point during the study.  
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Centre / country effects 
Treatment Satisfaction scores at baseline differed significantly between country pools, 
with the highest scores in Austrian (baseline mean 31.7) and the lowest scores in 
French (23.7) pools (Fig. 2).  Irrespective of these differences, however, the direction 
of response was largely identical across country pools, i. e. there was no country by 
treatment interaction (p=0.331).  With the exception of Norway and France, responses 
were more favourable, or less unfavourable, in the insulin glargine group than in the 
NPH group. 
Fig. 2 
Effect of previous treatment regimen 
Increases in Treatment Satisfaction with insulin glargine were observed irrespective 
of whether the patients had previously been on a once-daily or more than once-daily 
NPH insulin regimen.  In contrast, patients who switched back from insulin lispro to 
standard insulin at the start of the study showed significant reductions in Treatment 
Satisfaction compared with those who remained on standard insulin (p = 0.025).  
Nevertheless, the advantage of insulin glargine over NPH was still present, indicating 
that the difference between treatments was independent of the previous short-acting 
insulin.  Treatment Satisfaction with both treatments increased in the small number of 
patients who changed from conventional syringes to the OptiPen®.  Irrespective of 
the previous injection device, greater satisfaction was noted with insulin glargine than 
with NPH. 
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Discussion 
In this study, patients with Type 1 diabetes who started to use insulin glargine had 
greater satisfaction with treatment than those remaining on NPH insulin.  The 
difference in favour of insulin glargine was statistically significant at each study visit 
and increased over time.  The observed effect size fulfils the criteria for a clinically 
meaningful change (14).  There were only small changes in patients’ perception of 
metabolic control and insulin glargine showed a somewhat more favourable impact 
than NPH.  General Well-being increased during the study with both insulin glargine 
and NPH and there was no significant difference between the treatments. 
The study was not blinded and participants knew which treatment they were 
receiving.  It could be argued, therefore, that the increase in Treatment Satisfaction 
might have initially reflected patients being pleased with their allocation to the new 
insulin formulation. However, the early improvements in Treatment Satisfaction were 
maintained and even increased throughout the course of the study.  If all of the 
perceived benefits were introduced by unmet expectations of patients or clinicians 
these benefits should have been more transient.  Also physicians’ and patients’ 
attitudes do not necessarily go in the same direction. It should be noted that blinded 
designs have their weaknesses particularly in studying psychological effects of 
treatment. In the case of our study it is questionable whether blinding would have 
been successful. If blinding was successful, the experience of factors other than the 
pharmacological effect, such as the method and frequency of administration which 
affect the convenience of the treatment and its impact on lifestyle could have been 
missed.  The improvements in treatment satisfaction observed with insulin lispro are 
mainly attributable to the convenience of lispro in requiring no injection-meal 
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interval. Our individual item analysis showed improvements across most of the 
Treatment Satisfaction items, with particular emphasis on convenience and desire to 
continue treatment involving insulin glargine.  Such convenience-related treatment 
characteristics would be confused in a blinded design which, in the case of insulin 
glargine, would require additional placebo injections. 
The improvements in Treatment Satisfaction with insulin glargine were largely 
confirmed in the various subgroup analyses.  As expected from previous research (12, 
15), patients who switched back from insulin lispro to standard soluble insulin had 
marked reductions in satisfaction with treatment.  However, this did not affect the 
differences in responses between insulin glargine and NPH.  A similar pattern of 
responses was seen in most of the country pools except Norway where satisfaction 
improved slightly with NPH and deteriorated slightly with insulin glargine, and 
France and Denmark where satisfaction deteriorated in both treatment groups.  Since 
the pooled site by treatment interaction was not significant, however, the general 
applicability of the main results still holds. 
Psychological well-being increased in both treatment groups and this change involved 
all subscales of the W-BQ22 and W-BQ12 although not all subscales reached 
significance in their own right. The W-BQ12 showed a very similar pattern to that of 
the W-BQ22 with very little loss of sensitivity.  There was no difference between 
treatments in well-being scores. This is consistent with a non-specific study effect 
whereby participation in the clinical trial improved psychological well-being 
regardless of treatment allocation.  Insulin glargine was less likely to produce 
advantages over NPH insulin in psychological well-being than it was for Treatment 
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Satisfaction.  It is reassuring that there was no deterioration in well-being and that 
patients maintained their high levels of psychological well-being during the study. 
Although the DTSQ and W-BQ have been shown to be sensitive to change (15-17) 
the true treatment effect may have been underestimated in our study.  Like many other 
psychological outcome measures, the instruments often produce skewed distributions 
of scores and a proportion of respondents already have optimal scores at baseline (2, 
18).  This phenomenon of ceiling and floor effects, which limits opportunities for 
improvements (19, 20), was also observed in the present study population.  Despite 
this, a significant improvement in Treatment Satisfaction occurred in the insulin 
glargine group.  
Increases in Treatment Satisfaction were reported from a number of unblinded trials 
with insulin lispro in comparison with regular human insulin (12, 15, 17).  It would 
have been of interest to compare the magnitude of effect observed in these trials with 
our findings.  However, due to publication of cross-over results in aggregate form (21, 
22) the results of these trials are not suitable for meaningful comparison with our 
results. 
In conclusion, other studies of glargine versus NPH have reported improvements in 
metabolic outcomes of diabetes care (5, 6, 8). The present study also demonstrates 
improvements in Treatment Satisfaction with glargine including subjective 
perceptions of hyperglycaemia and hypoglycaemia which are consistent with 
objective findings.  A combination regimen of insulin glargine together with insulin 
lispro or another rapid-acting insulin is likely to improve these outcomes yet further.  
It will be worthwhile to explore this possibility in future research. 
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APPENDIX 
Diabetes Treatment Satisfaction Questionnaire (DTSQ) 
The DTSQ is an 8-item questionnaire that measures satisfaction with diabetes 
treatment.  Each of the eight items is scored on a scale from 0 to 6.  The DTSQ 
generates a sum score for Treatment Satisfaction from Items 1, 4, 5, 6, 7, and 8 (with 
a possible minimum (maximum) score of 0 (36), and two individual item scores for 
Perceived Frequency of Hyperglycaemia (Item 2) and Perceived Frequency of 
Hypoglycaemia (Item 3). Cronbach’s alpha coefficients ranged from 0.747 to 0.865 
for the translations used in this study (10). 
Well-being Questionnaire (W-BQ) 
The W-BQ22 is a 22-item questionnaire providing an overall measure of General 
Well-being (combining all 22 items) and is composed of four subscales: Depression 
(Items 1 - 6), Anxiety (Items 7 - 12), Energy (Items 13 - 16) and Positive Well-being 
(Items 17 - 22).  Each of the 22 items is scored on a scale from 0 to 3, where 0 = not 
at all, and 3 = all the time.  The W-BQ22 generates a sum score (0 – 66) and four 
subscale scores: Depression (0 – 18), Anxiety (0 – 18), Energy (0 – 12) and Positive 
Well-being (0 – 18). The W-BQ12 is an abbreviated version of the W-BQ22 with 12 
items, three subscales and an improved factor structure. Cronbach’s alpha coefficients 
for the translations used in this study ranged from 0.884 to 0.916 for the W-BQ22 and 
from 0.806 to 0.871 for the W-BQ12 (11). 
Translations of the DTSQ and W-BQ were improved as necessary prior to the study, 
particularly the Swedish Energy subscale. 
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Scoring 
The DTSQ and W-BQ scales and subscales are scored in the direction of the scale or 
subscale label, i.e., an increase in the score signifies an increase in the label.  For 
example, a higher score on General Well-being indicates greater well-being, and a 
higher score on the Depression subscale indicates more depressed mood. 
Access to questionnaires 
The DTSQ and W-BQ are presented and reviewed in (3, 9), together with scoring 
instructions and details of the psychometric development.  Access to the 
questionnaires and permission for use can be obtained from the copyright holder, 
Professor Clare Bradley, Health Psychology Research, Department of Psychology, 
Royal Holloway, University of London, Egham, Surrey TW20 0EX, UK. 
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Table 1. Demographic, clinical and psychological variables at baseline 
Variable Insulin glargine NPH 
n 261 256 
Age (years) 40.1 (12.31) 39.4 (11.90) 
Age range (years) 17 –77 18 – 77 
Sex (% male) 54.4 56.6 
GHb (%) 7.82 (1.15) 7.95 (1.15) 
Previous treatment (%)   
NPH once daily 49.8 50.4 
Insulin lispro 16.5 13.3 
OptiPen® 12.7 10.2 
Other pen 85.4 85.0 
Conventional syringes 2.0 4.9 
DTSQ scores:   
Treatment Satisfaction 27.84 (5.92) 28.09 (5.38) 
Perceived Frequency of 
Hyperglycaemia  
 
2.8 (1.48) 
 
3.0 (1.56) 
Perceived Frequency of 
Hypoglycaemia  
 
2.1 (1.40) 
 
2.1 (1.42) 
W-BQ scores:   
General Well-being 50.34 (9.01) 49.40 (9.25) 
Depression 3.50 (2.63) 3.58 (2.60) 
Anxiety 3.98 (3.03) 4.20 (3.22) 
Energy 8.49 (2.15) 7.91 (2.39)** 
Positive Well-being 13.33 (3.23) 13.18 (2.96) 
All data (except n, age range, sex % male and previous treatment %) are means (± 
SD) 
** significant difference between treatment groups,  p<0.01 
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Table 2. Psychological outcomes: an overview 
 
 Changes from baseline to endpoint within treatment groups Differences in changes from baseline to 
endpoint between treatment groups 
 Insulin 
glargine 
p value NPH p value ∆ 95% CI p value 
DTSQ:        
Treatment Satisfaction 1.27 0.001** -0.56 NS 1.83 0.82; 2.84 < 0.001*** 
Perceived Frequency of 
Hyperglycaemia 
 
-0.55 
 
< 0.001*** 
 
-0.30 
 
< 0.001*** 
 
-0.3 
 
-0.49, -0.02 
 
0.038* 
Perceived Frequency of 
Hypoglycaemia 
 
0.10 
 
NS 
 
0.15 
 
NS 
 
-0.0 
 
-0.27, 0.18 
 
NS 
W-BQ22:        
General Well-being 1.22 0.005** 1.57 < 0.001*** -0.35 -1.50; 0.81 NS 
Depression -0.19 NS -0.24 NS 0.06 -0.31: 0.42 NS 
Anxiety -0.31 0.039* -0.53 < 0.001*** 0.22 -0.17; 0.62 NS 
Energy 0.33 0.008** 0.40 0.001** -0.07 -0.40; 0.25 NS 
Positive Well-being 0.39 0.017* 0.35 0.030* 0.04 -0.39; 0.46 NS 
W-BQ12:        
General Well-being 0.78 0.004** 1.12 < 0.001*** -0.34 -1.05; 0.37 NS 
Negative Well-being -0.22 NS -0.52 < 0.001*** 0.29 -0.01; 0.60 NS 
Positive Well-being 0.24 0.0344 0.21 NS 0.03 -0.27; 0.32 NS 
All data are adjusted means.  95% CI = 95% confidence interval of adjusted means.  * < 0.05, ** < 0.01, *** < 0.001, NS = not significant. 
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Table 3. Treatment Satisfaction: individual item analysis 
 
DTSQ Item Changes from baseline to endpoint within 
treatment groups 
Differences in changes from baseline to 
endpoint between treatment groups 
 Insulin glargine NPH ∆ p value 
Item 1: Satisfaction 0.37 0.08 0.29 0.002** 
Item 4: Convenience 0.32 0.09 0.41 < 0.001***
Item 5: Flexibility 0.25 0.00 0.25 < 0.001***
Item 6: Understanding -0.03 0.06 -0.09 NS 
Item 7: Recommend to others 0.00 -0.31 0.32 0.003** 
Item 8: Wish to continue 0.39 -0.24 0.63 <0.001***
All data are adjusted means. * < 0.05, ** < 0.01, *** < 0.001, NS = not significant. 
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Legends for Figures 
 
Figure 1. Time profile of changes from baseline in Treatment Satisfaction 
Figure 2. Change in Treatment Satisfaction by country
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Figure 2. Change in Treatment Satisfaction by country 
 
 
-6.00
-4.00
-2.00
0.00
2.00
4.00
SWE  NL   FIN   UK  GER* AUT  NOR FRA DEN
44    25     40     34   124     82      21   101    46
Number of patients per country pool
* includes 13 patients from Switzerland
de
cr
ea
se
   
↔
   
in
cr
ea
se
        Insulin glargine          NPH
